Allogene Therapeutics, Inc.

Stage 4 · Declining · week 6

As of Oct 22, 2026, Allogene Therapeutics is in Stage 4, the downtrend phase, now in week 6 (since Sep 15, 2026). It closed at $1.25, 59.2% below its 52-week high and below its 200-day average, which is rising.

$1.25

-6.01% today

$432M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ALLO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S4 36w

S2 21w

S3 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 21w → S1 8w → S2 7w → S3 4w → S4 11w → S1 9w → S4 2w → S1 4w → S4 36w → S1 2w → S4 9w → S1 9w → S2 21w → S3 14w → S2 2w → S1 1w → S4 5w current

Total tracked: 166 weeks across 17 stage runs.

ALLO among Biotechnology191st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…191	ALLOAllogene Therapeutics, Inc.	Stage 4 · wk 6	53	−25.1%

vs 52W High

-59.2%

$1.05 lo$3.06 hi

59.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-37.2%

200 DMA: $1.99 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.51x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-25.1%

-28.2%

-46.8%

YTD

-7.4%

-0.8%

Scan Membership

Breakout Watch

Latest: 2024-03-07

6 appearances in last 60 days. First seen: 2019-09-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 1.51x

2026-10-21S4

Wk 6 · Vol 0.86x

2026-10-20S4

Wk 6 · Vol 0.83x

2026-10-19S4

Wk 5 · Vol 1.08x

2026-10-16S4

Wk 5 · Vol 0.90x

2026-10-15S4

Wk 5 · Vol 0.83x

2026-10-14S4

Wk 5 · Vol 1.43x

2026-10-13S4

Wk 5 · Vol 1.21x

2026-10-12S4

Wk 4 · Vol 0.79x

2026-10-09S4

Wk 4 · Vol 1.95x

2026-10-08S4

Wk 4 · Vol 1.45x

2026-10-07S4

Wk 4 · Vol 0.69x

Moving averages & range

50 DMA

$1.72

200 DMA

$1.99

52W High

$3.06

52W Low

$1.05

5D Low

$1.25

Resistance levels (recent highs)

20d High

$1.65

60d High

$2.23

120d High

$2.33

250d High

$3.06

Next resistance

+32.0%

to 20d High

ROE

-42.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.0

Allogene Therapeutics: quick answers

What stage is Allogene Therapeutics in?

As of Oct 22, 2026, Allogene Therapeutics (ALLO) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 15, 2026 and is in week 6. What the four stages mean

Is Allogene Therapeutics in an uptrend?

No. Allogene Therapeutics is in a Stage 4 downtrend. It trades 37.2% below its 200-day average, which is rising.

How far is Allogene Therapeutics from its 52-week high?

Allogene Therapeutics closed at $1.25 on Oct 22, 2026, 59.2% below its 52-week high of $3.06. Its 52-week low is $1.05.

How has Allogene Therapeutics performed over the past year?

As of Oct 22, 2026, Allogene Therapeutics is down 0.8% over the past year and down 7.4% so far in 2026.

Which sector and industry is Allogene Therapeutics in?

Allogene Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.